Locus-coeruleus function in normal elderly and AD risk (LEAD)
(S,S)-[11C]Methylreboxetine ((S,S)-[11C]MRB) is a radioligand developed for positron emission tomography (PET) imaging of the brain adrenergic receptors. In ongoing clinical studies, 11C-MRB PET is currently being examined to determine whether the tracer has utility in the differential diagnosis and follow-up of Alzheimer’s disease risk and in evaluating the efficacy of preventive therapies. To enable the continued use of 11C-MRB and to confirm safety, it is important to determine the radiation exposure caused by such studies. The use of this tracer has been approved by the FDA since 2005. This tracer has been used for PET imaging of over 500 human studies with no major side effects. Before this tracer can be used in our main study, the dosimetry results need to be analyzed and reported locally prior to the start of the study.
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults
This study seeks to meaningfully address the U.S. opioid epidemic by comparing the effectiveness of two medications used to treat opioid use disorder, extended-release buprenorphine (XR-B) vs. extended-release naltrexone (XR-NTX), among adults currently incarcerated in U.S. jails and prisons at 5 distinct trial sites. This open-label, non-inferiority, head-to-head study design will allow providers, correctional and public health authorities, payers and policy makers' timely and relevant data to assess the effectiveness of XR-B (and XR-NTX) as potentially useful re-entry treatment option. Considering the majority of opioid users leaving jail or prison will inevitably return to their homes and communities untreated and prone to relapse, we believe findings from with important implications for limiting the greater public safety and societal costs of heroin, fentanyl, and prescription opioid addictions. Comparing retention-in-study-medication treatment, we hypothesize XR-B is non-inferior to XR-NTX.
Long Island Community Hospital | NYU Langone Health
The team at Long Island Community Hospital, an affiliate of NYU Langone Health, provides medical care to residents of eastern Long Island.
Long-term Cardiac Device Lead Management | NYU Langone Health
NYU Langone electrophysiologists are experienced in safely replacing cardiac device batteries or leads when necessary.
Long-Term Follow-Up Study of Patients with Spinal Muscular Atrophy Receiving Risdiplam Treatment
This study will evaluate the long-term safety and effectiveness of risdiplam (Evrysdi?),prescribed on the basis of the U.S. Package Insert (USPI) and clinician judgement, in adult and pediatric spinal muscular atrophy (SMA) patients.
Lower Extremity Arterial Disease | NYU Langone Health
NYU Langone doctors can help you manage the symptoms of lower extremity arterial disease.
Lung Cancer | NYU Langone Health
At NYU Langone’s Perlmutter Cancer Center, our specialists treat non-small cell and small cell lung cancer, and mesothelioma.
Lung Cancer Center | NYU Langone Health
Lung Cancer Center experts at NYU Langone’s Perlmutter Cancer Center provide individualized care for people with lung cancer and mesothelioma.
Lung Cancer Center Leadership | NYU Langone Health
NYU Langone’s Lung Cancer Center is led by a team of experts in lung cancer treatment and research.
Lung Cancer Screening Program | NYU Langone Health
NYU Langone’s Lung Cancer Screening Program offers testing for men and women at risk for lung cancer.